Following FDA approval earlier this year, Rezzayo (Rezafungin acetate) became the initial drug authorized for candidemia and invasive candidiasis treatment in over a decade.
Following FDA approval earlier this year, Rezzayo (Rezafungin acetate) became the initial drug authorized for candidemia and invasive candidiasis treatment in over a decade.
